In Brief: FemRx
This article was originally published in The Gray Sheet
Executive Summary
FemRx: Plans on launching its Diva laparoscopic morcellator for use with the firm's OPERA (Out-Patient Endometrial Resection/Ablation) system during the third quarter, Andrew Thompson, president and chief executive officer of FemRx said at the June 19 Dillon, Read & Co. Medical Technology meeting in New York City. During the fourth quarter FemRx plans on launching its Pearl technology, which allows OPERA equipment to be used with normal saline. In 1998 the company plans on introducing the StarLight, which will be "the smallest continuous flow resectoscope on the market," Thompson said. FemRx also is developing the Soprano cryothermic global ablation system, which the company hopes to introduce in 1999...
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.